biostock research replies

David Miller from Biostock Research has replied to my email to them about Prima possibly being the next Dendreon.

I have since replied to him clarifying a bit more eg Prima are not using 'late stage' patients in the Phase 2b trials but rather 'later stage' ones who are in remission after chemo (and as I believe are still quite well).

He obviously is yet to be convinced about Prima and from the speed of his reply,I don't think he took too long in absorbing all the details about CVac.A pity but maybe he will revisit the website and do a bit more reseach on the Cvac technology and the company.

here is what he wrote:

"It's an interesting approach. I'm not aware of anyone who has succeeded in creating in-vivo viable DCs by cloning them. Dendreon, JNJ, Genentech, and others failed. Perhaps Prima does have the tech,
but it is a significant difference between this technology and Dendreon's.

Also, using late-stage patients outside of prostate cancer is a deduction of points, not an addition. This is especially true in ovarian cancer. The need is great, but we catch most women very late.
That said, Dendreon is also trying their next drug in ovarian (and bladder) though both in earlier stages of the disease.

I looked at Prima's latest investor presentation from their web site. I think I've met someone from management at a conference event.

Thanks for the tip and good luck with the investment,

David"